Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02202148
Other study ID # 2014-A00854-43
Secondary ID
Status Completed
Phase N/A
First received July 25, 2014
Last updated January 30, 2017
Start date July 2015
Est. completion date December 2016

Study information

Verified date January 2017
Source Centre Hospitalier Esquirol
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is complementary to the main study "Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal " NCT01491347.

Liver stiffness variation is one of the major somatic effect of chronic alcohol consumption. It is a consequence of numerous mechanisms, including inflammation. Liver stiffness seems to depend on alcohol consumption in alcohol dependent patient, more precisely on the time after the last alcohol consumption. This is very few documented after alcohol withdrawal, and has never been explored during several months after withdrawal as a function of alcohol consumption and abstinence.

Brain Derived neurotrophic Factor (BDNF) seems to play a major role in general homeostasis and also liver function.

We propose here to analyse the serum BDNF levels variations after withdrawal according to liver stiffness levels and alcohol consumption status.

We will also measure liver stiffness using Fibroscan® in alcohol dependent subjects included in the main study to search for a link with serum BDNF levels and abstinence at day 0, 14, 28 and months 2, 4, and 6.


Recruitment information / eligibility

Status Completed
Enrollment 195
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- participation to the study "BDNF serum levels evolution during 6 months after alcohol withdrawal" (main study)

- criteria from the main study

Exclusion Criteria:

- criteria from the main study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Centre Hospitalier Esquirol Limoges

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Esquirol Hôpital Dupuytren

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary BDNF serum levels as a function of stiffness categories in the abstinent and non abstinent groups at inclusion and at the different follow-ups of the study (M2, M4, M6) 6 months maximum
Secondary serum BDNF levels variations between inclusion and M2, M2 and M4 and M4 and M6. 6 months
Secondary liver stiffness categories according to stiffness measurements at inclusion, M2, M4 and M6 6 months
Secondary Variations in liver stiffness 6 months
Secondary controlled attenuation parameter (CAP) at each follow-up 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT03916939 - Osteopathic Treatment to Alcohol Withdrawal Syndrome N/A
Completed NCT04858490 - Remote Treatment of Alcohol Withdrawal N/A
Not yet recruiting NCT04997330 - Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction N/A
Recruiting NCT04876443 - Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
Completed NCT05131334 - Auricular Vagal Stimulation in Alcohol Craving N/A
Completed NCT02349477 - Gabapentin for Alcohol Relapse Prevention Phase 2
Terminated NCT01937364 - Preventing Alcohol Withdrawal With Oral Baclofen Phase 2
Completed NCT05393544 - Digitally Assisted Recovery Coach N/A
Completed NCT00523185 - A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal N/A
Not yet recruiting NCT06173973 - Effects of Ketone Supplementation on Acute Alcohol Withdrawal Phase 2/Phase 3
Completed NCT01573052 - Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Phase 4
Active, not recruiting NCT03737864 - NCARE, Transition to Recovery N/A
Recruiting NCT03878225 - Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans? N/A
Terminated NCT03586089 - Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome N/A
Recruiting NCT04156464 - Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit Phase 4
Completed NCT02251912 - Oxytocin Treatment of Alcohol Dependence Phase 2
Completed NCT01212185 - Oxytocin Treatment of Alcohol Withdrawal Phase 1
Recruiting NCT04793685 - Prazosin for Alcohol Use Disorder With Withdrawal Symptoms Phase 1/Phase 2
Withdrawn NCT04159909 - Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal N/A
Completed NCT05563350 - Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms